| Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity (NCT00942838) | University of Utah | 2009-07-01 |
| Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01001910) | Albert Einstein College of Medicine | 2008-07-01 |
| A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT00671788) | Gynecologic Oncology Group | 2008-06-01 |
| Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy (NCT00602277) | National Cancer Institute (NCI) | 2008-04-01 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00565851) | National Cancer Institute (NCI) | 2007-12-06 |
| Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy (NCT00551265) | Gynecologic Oncology Group | 2007-10-01 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00499252) | Gynecologic Oncology Group | 2007-06-01 |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (NCT00410553) | National Cancer Institute (NCI) | 2006-11-14 |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors (NCT00301756) | National Cancer Institute (NCI) | 2006-09-01 |
| Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer (NCT00093626) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00096200) | National Cancer Institute (NCI) | 2004-08-01 |
| Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00072566) | National Cancer Institute (NCI) | 2003-12-01 |
| Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00066456) | Gynecologic Oncology Group | 2003-09-01 |
| Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00054119) | Gynecologic Oncology Group | 2003-01-01 |
| CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00045682) | Gynecologic Oncology Group | 2002-09-01 |
| Collecting Tumor Samples From Patients With Gynecological Tumors (NCT00897442) | Gynecologic Oncology Group | 1992-06-01 |